[ad_1] MILAN, Italy & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, a leading biopharmaceutical company with operations in Italy and the US, today announced the appointment of Shannon K. Sullivan as Chief Commercial…
Tag: BioSpace
Transgene and BioInvent – First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab) | BioSpace
[ad_1] STRASBOURG, France & LUND, Sweden–(BUSINESS WIRE)– Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq…
Biopharma Layoff Tracker 2023: Atsena, uniQure, Kezar and More Cut Staff | BioSpace
[ad_1] 2022 saw myriad ups and downs in terms of the economy, and as it ebbed and flowed, so too did the job market. This trend has continued throughout 2023.…
Newron Appoints Margarita Chavez as Board Advisor | BioSpace
[ad_1] MILAN–(BUSINESS WIRE)– Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral…
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company | BioSpace
[ad_1] — Conley Chee, CCO and CBO, to succeed Nancy Simonian, M.D. as CEO; Dr. Simonian to retire as CEO, effective December 1, 2023, and will remain on the Board…
Zhongchao Inc. Introduces PRO-Based Disease Management Model for Lung Cancer Patients | BioSpace
[ad_1] SHANGHAI, Sept. 25, 2023 /PRNewswire/ — Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a platform-based internet technology company offering services for patients with cancer…
5 Life Sciences IPOs in 2023—and the Future Forecast | BioSpace
[ad_1] Pictured: Stock prices shown on computer and mobile screens/iStock Compared to recent years, 2023 has been a relative desert—or a winter—in terms of biotech IPO offerings. In 2022, for…
Aiosyn Introduces Kidney AI Platform to Revolutionize Renal Disease Research | BioSpace
[ad_1] NIJMEGEN, Netherlands–(BUSINESS WIRE)– Aiosyn, a medical software company specializing in AI-powered pathology solutions, has announced the release of an AI kidney suite designed to advance research in the field…
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines | BioSpace
[ad_1] – With the recently announced definitive agreement to acquire Small Pharma Inc. The granted patent will add to the most impressive intellectual property portfolio in the psychedelic drug development…